EWPI Emerging World Pharma Inc (CE)

Emerging World Pharma Inc. (PINKSHEETS: EWPI) -- Strategic partner, African Global Pharma (AGP), has now completed all regulatory requirements for production at its Sunyani, Ghana facility. Samples and dossiers of the AGP product line are currently awaiting final approval from the Food and Drug Board of Ghana.

EWPI Company President Brandon Keks acknowledges the delays in bringing AGP to full production readiness. "African Global Pharma has experienced considerable delays in receiving full product approval. However unfortunate, this extra time has allowed AGP to ensure its facility exceeds FDB standards and that all staff are fully trained and ready. We are excited to see AGP's products approved and in full production by the end of 2011."

The company expects a subsequent update on additional progress within 5 business days.

www.emergingpharma.com

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret Emerging World Pharma Inc. Investor Relations Division 703-646-2633 Email: info@emergingpharma.com